IonSource Daily Links to 
Mass Spectrometry, Biotechnology and Pharmaceutical  Industry News


IonSource Home | Disclaimer

Note: News stories may be minutes or several days old and should not be used for investment purposes.



11/08/15 Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
  New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
11/07/15 Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis
  GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
11/05/15 Pfizer Global Analysis Of Metastatic Breast Cancer Landscape Reveals Gaps In Patient Care And Support
  European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma
  Further refugee aid measure:
Bayer donates medicines for refugees in Turkey, Greece and Austria
  Agilent Technologies Signs Instrument Control Exchange Agreement with Thermo Fisher Scientific
  U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
11/04/15 Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
  GSK’s Nucala® (mepolizumab) receives approval from US FDA  First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
  Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
11/03/15 Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers
  ISS and Glass Lewis Recommend Horizon Pharma Shareholders Vote AGAINST the Issuance of Horizon Shares in Connection with Horizon's Attempted Takeover of Depomed
11/02/15 New Data Continue to Characterize the Safety and Efficacy of XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis
  Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc
  Agilent Technologies Completes Acquisition of Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
  Bruker eDispatch, Issue 63, November 2015 Get the latest news for Separations & Mass Spec with Bruker's eDispatch monthly Newsletter
10/28/15 Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma
  Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product
10/27/15 Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
10/23/15 Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus Differently Than Existing Treatments
10/14/15 Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
10/09/15 Dako, an Agilent Technologies Company, Announces FDA Approval of New Test for Lung Cancer Patients
10/08/15 Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
10/07/15 Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies
10/06/15 Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020
10/02/15 Bayer CropScience hosts Weed Resistance Global Symposium in Paris:
Knowledge exchange, collaboration and innovation are key to fighting global weed resistance more
  FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
10/01/15 Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
  Bayer CropScience hosts Horticulture Symposium in Mexico:
Joining hands for sustainability and innovation in horticulture
9/30/15 Thermo Fisher Scientific Completes Acquisition of Alfa Aesar to Significantly Expand Laboratory Chemicals Offering
9/29/15 Shimadzu's Nexera MX Ultra Fast Multianalyte LCMS System Offers Excellent Operational Efficiency and Up to Double the Previous Sample Processing Capability
9/28/15 Roche's ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
  Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO
9/27/15 Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057
  Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study
9/25/15 Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
  Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma
  Bruker’s NMR FoodScreener™ Laboratory Achieves ISO/IEC 17025 Accreditation
9/24/15 SCIEX Announces Exclusive Reseller Agreement with Advaita Bioinformatics
  Development of new wheat varieties in Saxony-Anhalt:
Bayer CropScience expands its European Center for Wheat Breeding in Gatersleben
  GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma
9/23/15 New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
  Agilent Technologies Announces Opening of Life Science Research Center at Carleton University
  Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes
9/16/15 Amgen To Acquire Privately-Held Dezima Pharma
9/9/15 Gilead Prices $10 Billion of Senior Unsecured Notes
9/8/15 FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
  Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.

Company News

On-Line Magazines Hot News Sites

BMS Company
Eli Lilly
Incyte Gen.
Life Technologies

LCGC Magazine
Drug Discovery and Development Magazine
New Scientist

Proteomic Company News Links
Check out the Proteomics page at IonSource 

GE News of the Day
ScienceNews On-Line
The Seattle Times
SF Gate Technology News


Archive of old news 

home | disclaimer
Copyright © 2001-2015  IonSource, LLC  All rights reserved. 
Last updated:  Sunday, November 08, 2015 08:55:31 PM

Hit Counter